{
  "event_id": "fff8d4edb321",
  "ticker": "SNDX",
  "company_name": "Syndax Pharmaceuticals",
  "drug_name": "Revuforj revumenib",
  "pdufa_date": "20251024",
  "approval_type": {
    "status": "found",
    "value": "nda",
    "source": "websearch:AUGMENT-101 Phase 2 (Approved 2024, Oct 2025 NPM1)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.614843",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "R/R AML with KMT2A/NPM1",
    "source": "websearch:AUGMENT-101 Phase 2 (Approved 2024, Oct 2025 NPM1)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.614845",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "revumenib",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:39:43.834535",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Oncology",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:59.079369",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T00:39:43.834535",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:AUGMENT-101 Phase 2 (Approved 2024, Oct 2025 NPM1)",
    "confidence": 0.9,
    "evidence": [
      "AUGMENT-101 Phase 2 (Approved 2024, Oct 2025 NPM1)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.614831",
    "error": null
  },
  "p_value": {
    "status": "found",
    "value": "p==0.0036",
    "source": "websearch",
    "confidence": 0.9,
    "trial": "AUGMENT-101",
    "tier": 2
  },
  "p_value_numeric": 0.0036,
  "effect_size": {
    "status": "found",
    "value": "CR/CRh 23-25%",
    "source": "websearch:AUGMENT-101 Phase 2 (Approved 2024, Oct 2025 NPM1)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.614840",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation",
    "Expanded Access Program for SNDX-5613 in Patients With Relapsed/Refractory Acute Leukemias With Genetic Alterations Associated With HOXA Overexpression",
    "A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia"
  ],
  "nct_ids": [
    "NCT04065399",
    "NCT05918913",
    "NCT05761171"
  ],
  "enrollment": {
    "count": 413,
    "type": "ESTIMATED",
    "nct_id": "NCT04065399",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:30:31.894466"
  },
  "has_prior_crl": {
    "status": "found",
    "value": false,
    "source": "derived_from_first_submission",
    "confidence": 0.95,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 0,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:17:15.118968",
  "enriched_at": "2026-01-11T20:16:17.533186",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "a10bb0645482",
  "fda_designations": {
    "breakthrough_therapy": true,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": true
  },
  "mechanism_of_action": "Menin inhibitor",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -78,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:42.083356",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:16.943715"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:16.943722"
  },
  "breakthrough_therapy": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Syndax Announces FDA Approval of Revuforj速 (revumenib), the ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:16:03.061459",
    "search_status": "FOUND"
  },
  "orphan_drug": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Syndax Announces FDA Approval of Revuforj速 (revumenib), the ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:16:04.171906",
    "search_status": "FOUND"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Syndax Announces FDA Priority Review of sNDA for Revuforj速"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:16:07.704674",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Syndax Announces FDA Approval of Revuforj速 (revumenib) in"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:16:11.365172",
    "search_status": "FOUND"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:16:17.533154",
    "search_status": "CONFIRMED_NONE"
  }
}